Martin Schiestl

1.1k total citations
19 papers, 472 citations indexed

About

Martin Schiestl is a scholar working on Immunology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Martin Schiestl has authored 19 papers receiving a total of 472 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Immunology, 8 papers in Molecular Biology and 6 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Martin Schiestl's work include Biosimilars and Bioanalytical Methods (19 papers), Protein purification and stability (7 papers) and Monoclonal and Polyclonal Antibodies Research (6 papers). Martin Schiestl is often cited by papers focused on Biosimilars and Bioanalytical Methods (19 papers), Protein purification and stability (7 papers) and Monoclonal and Polyclonal Antibodies Research (6 papers). Martin Schiestl collaborates with scholars based in Austria, Switzerland and Germany. Martin Schiestl's co-authors include Thomas Stangler, Cornelius Fritsch, Timo Schmiederer, Isabel Feuerstein, Fritz Sörgel, Andriy Krendyukov, William C. Lamanna, Andreas Seidl, Johann Holzmann and Hillel P. Cohen and has published in prestigious journals such as SHILAP Revista de lepidopterología, Scientific Reports and Trends in Pharmacological Sciences.

In The Last Decade

Martin Schiestl

19 papers receiving 442 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Martin Schiestl Austria 12 353 161 159 109 90 19 472
Gustavo Grampp United States 11 235 0.7× 122 0.8× 167 1.1× 112 1.0× 75 0.8× 24 506
Venke Skibeli Norway 8 206 0.6× 41 0.3× 123 0.8× 75 0.7× 61 0.7× 10 428
Hans C. Ebbers Netherlands 14 514 1.5× 89 0.6× 60 0.4× 288 2.6× 196 2.2× 31 645
Elena Wolff‐Holz Germany 10 576 1.6× 95 0.6× 51 0.3× 293 2.7× 225 2.5× 19 681
Camille Vleminckx Netherlands 6 356 1.0× 86 0.5× 34 0.2× 161 1.5× 120 1.3× 7 430
Leon van Aerts Netherlands 3 361 1.0× 62 0.4× 21 0.1× 175 1.6× 126 1.4× 3 437
Evelien Moorkens Belgium 10 258 0.7× 51 0.3× 66 0.4× 218 2.0× 73 0.8× 17 360
Reginald B. Ewesuedo United States 11 139 0.4× 81 0.5× 233 1.5× 22 0.2× 31 0.3× 29 450
E.C. Faulkner United States 9 64 0.2× 47 0.3× 121 0.8× 135 1.2× 19 0.2× 20 500
Sigrid Balser United States 10 125 0.4× 21 0.1× 44 0.3× 31 0.3× 53 0.6× 15 303

Countries citing papers authored by Martin Schiestl

Since Specialization
Citations

This map shows the geographic impact of Martin Schiestl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martin Schiestl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martin Schiestl more than expected).

Fields of papers citing papers by Martin Schiestl

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Martin Schiestl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martin Schiestl. The network helps show where Martin Schiestl may publish in the future.

Co-authorship network of co-authors of Martin Schiestl

This figure shows the co-authorship network connecting the top 25 collaborators of Martin Schiestl. A scholar is included among the top collaborators of Martin Schiestl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Martin Schiestl. Martin Schiestl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
2.
Dey, Dzifa, et al.. (2020). Determinants of Use of Biotherapeutics in sub-Saharan Africa. Trends in Pharmacological Sciences. 42(2). 75–84. 11 indexed citations
3.
Schiestl, Martin, et al.. (2020). The Path Towards a Tailored Clinical Biosimilar Development. BioDrugs. 34(3). 297–306. 41 indexed citations
4.
Krendyukov, Andriy & Martin Schiestl. (2019). Biosimilars in oncology: A decade of experience with granulocyte colony-stimulating factor and its implications for monoclonal antibodies. Critical Reviews in Oncology/Hematology. 102785–102785. 4 indexed citations
5.
Stangler, Thomas & Martin Schiestl. (2019). Similarity assessment of quality attributes of biological medicines: the calculation of operating characteristics to compare different statistical approaches. SHILAP Revista de lepidopterología. 5(1). 5 indexed citations
6.
Aapro, Matti, Andriy Krendyukov, Martin Schiestl, & Pere Gascón. (2018). Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years’ Experience Gained. BioDrugs. 32(2). 129–135. 12 indexed citations
7.
Mielke, Johanna, et al.. (2018). The Assessment of Quality Attributes for Biosimilars: a Statistical Perspective on Current Practice and a Proposal. The AAPS Journal. 21(1). 7–7. 3 indexed citations
8.
Goldsmith, David, Frank Dellanna, Martin Schiestl, Andriy Krendyukov, & Christian Combe. (2018). Epoetin Biosimilars in the Treatment of Renal Anemia: What Have We Learned from a Decade of European Experience?. Clinical Drug Investigation. 38(6). 481–490. 23 indexed citations
9.
Krendyukov, Andriy & Martin Schiestl. (2018). Extrapolation concept at work with biosimilar: a decade of experience in oncology. ESMO Open. 3(2). e000319–e000319. 13 indexed citations
10.
Lamanna, William C., Michael Fuchs, Fabian Higel, et al.. (2017). The structure-function relationship of disulfide bonds in etanercept. Scientific Reports. 7(1). 3951–3951. 27 indexed citations
11.
Lamanna, William C., et al.. (2017). The in-use stability of the rituximab biosimilar Rixathon®/Riximyo® upon preparation for intravenous infusion. Journal of Oncology Pharmacy Practice. 25(2). 269–278. 21 indexed citations
12.
Schiestl, Martin, et al.. (2017). Ten years of biosimilars in Europe: development and evolution of the regulatory pathways. Drug Design Development and Therapy. Volume 11. 1509–1515. 62 indexed citations
13.
Krendyukov, Andriy, et al.. (2017). Clinical equivalence with G-CSF biosimilars: methodologic approach in a (neo)adjuvant setting in non-metastatic breast cancer. Supportive Care in Cancer. 26(1). 33–40. 4 indexed citations
14.
Lamanna, William C., Johann Holzmann, Hillel P. Cohen, et al.. (2017). Maintaining consistent quality and clinical performance of biopharmaceuticals. Expert Opinion on Biological Therapy. 18(4). 369–379. 44 indexed citations
15.
Strand, Vibeke, et al.. (2017). The totality-of-the-evidence approach to the development and assessment of GP2015, a proposed etanercept biosimilar. Current Medical Research and Opinion. 33(6). 993–1003. 21 indexed citations
16.
Schiestl, Martin & Christoph Roesli. (2016). Development and Analytical Characterization of GP2017: A Proposed Adalimumab Biosimilar. The American Journal of Gastroenterology. 111. S289–S289. 5 indexed citations
17.
Feuerstein, Isabel, et al.. (2013). Physicochemical and Functional Comparability Between the Proposed Biosimilar Rituximab GP2013 and Originator Rituximab. BioDrugs. 27(5). 495–507. 148 indexed citations
18.
Schiestl, Martin, et al.. (2013). The role of the quality assessment in the determination of overall biosimilarity: A simulated case study exercise. Biologicals. 42(2). 128–132. 19 indexed citations
19.
Schiestl, Martin. (2011). A biosimilar industry view on the implementation of the WHO guidelines on evaluating similar biotherapeutic products. Biologicals. 39(5). 297–299. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gustavo Grampp Breakdown of academic impact, for papers by Venke Skibeli Breakdown of academic impact, for papers by Hans C. Ebbers Breakdown of academic impact, for papers by Elena Wolff‐Holz Breakdown of academic impact, for papers by Camille Vleminckx Breakdown of academic impact, for papers by Leon van Aerts Breakdown of academic impact, for papers by Evelien Moorkens Breakdown of academic impact, for papers by Reginald B. Ewesuedo Breakdown of academic impact, for papers by E.C. Faulkner Breakdown of academic impact, for papers by Sigrid Balser
Rankless by CCL
2026